Trial Profile
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Mar 2022
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 15 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2014 New trial record